These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32324120)

  • 1. Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
    Ferraz-Amaro I; Delgado-Frías E; Hernández-Hernández V; Sánchez-Pérez H; de Armas-Rillo L; García-Dopico JA; Díaz-González F
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):18-24. PubMed ID: 32324120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity.
    de Armas-Rillo L; Quevedo-Abeledo JC; de Vera-González A; González-Delgado A; García-Dopico JA; Jimenez-Sosa A; Rodríguez-Lozano C; González-Gay MA; Ferraz-Amaro I
    Rheumatology (Oxford); 2021 May; 60(5):2296-2306. PubMed ID: 33295631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
    Ferraz-Amaro I; López-Mejías R; Ubilla B; Genre F; Tejera-Segura B; de Vera-González AM; González-Rivero AF; Olmos JM; Hernández JL; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6):1013-1019. PubMed ID: 27606890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease.
    Aydogan Baykara R; Yilmaz PD; Göktepe MH; Kadiyoran C; Ogul M; Kucuk A; Cumhur Cüre M; Cüre E
    Clin Exp Hypertens; 2022 Jul; 44(5):480-486. PubMed ID: 35502687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus.
    Sánchez-Pérez H; Quevedo-Abeledo JC; Tejera-Segura B; de Armas-Rillo L; Rúa-Figueroa I; González-Gay MA; Ferraz-Amaro I
    Ther Adv Musculoskelet Dis; 2020; 12():1759720X20975904. PubMed ID: 33294038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis: A marker of disease activity and severe disease manifestations with potential therapeutic implementations.
    Artin J; Elsabagh YA; Rashed L; Hussein MA
    Arch Rheumatol; 2023 Jun; 38(2):249-256. PubMed ID: 37680510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Guo W; Gong Y; Li J; Qin P; Lu J; Li X; Zhu W; Xu N; Zhou H; Zhang Q
    Nutr Metab Cardiovasc Dis; 2019 Aug; 29(8):815-821. PubMed ID: 31133497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
    Liu A; Rahman M; Hafström I; Ajeganova S; Frostegård J
    Lupus; 2020 Jul; 29(8):825-835. PubMed ID: 32479241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin kexin type 9 and main artery atherosclerosis in patients with arterial hypertension.
    Vukolova Y; Gubareva I; Galati G; Germanova O
    Minerva Cardiol Angiol; 2023 Apr; 71(2):129-134. PubMed ID: 35420281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.
    Chan DC; Pang J; McQuillan BM; Hung J; Beilby JP; Barrett PH; Watts GF
    Heart Lung Circ; 2016 May; 25(5):520-5. PubMed ID: 26706651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.
    Kunimura A; Miura K; Segawa H; Torii S; Kondo K; Hisamatsu T; Kadota A; Fujiyoshi A; Yano Y; Nakagawa Y; Okamura T; Ueshima H
    J Atheroscler Thromb; 2023 Jul; 30(7):767-777. PubMed ID: 36123046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.
    Lee CJ; Lee YH; Park SW; Kim KJ; Park S; Youn JC; Lee SH; Kang SM; Jang Y
    Metabolism; 2013 Jun; 62(6):845-50. PubMed ID: 23380568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Elevated level of serum PCSK9 in patients with systemic lupus erythematosus].
    Fang C; Luo T; Chen X; Lin L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):541-545. PubMed ID: 30236208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias.
    Vlachopoulos C; Koutagiar I; Terentes-Printzios D; Skoumas I; Rigatou A; Miliou A; Skliros AN; Pantou S; Filis K; Tousoulis D
    Hellenic J Cardiol; 2019; 60(2):124-128. PubMed ID: 29807195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.
    Kunimura A; Yano Y; Hisamatsu T; Torii S; Kondo K; Kadota A; Fujiyoshi A; Okamura T; Watanabe Y; Shiino A; Nozaki K; Ueshima H; Miura K;
    Eur J Neurol; 2023 May; 30(5):1327-1334. PubMed ID: 36727585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus.
    Fang C; Luo T; Lin L
    Ann Transl Med; 2018 Dec; 6(23):452. PubMed ID: 30603640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.